tbuckley/cabot-search huggingface dataset:
Pain, activities of daily living and sport function at different time points after hip arthroscopy in patients with femoroacetabular impingement: a systematic review with meta-analysis
Authors: Signe Kierkegaard, Martin Langeskov-Christensen, Bent Lund, Florian D Naal, Inger Mechlenburg, Ulrik Dalgas, Nicola C Casartelli
Journal: British Journal of Sports Medicine (2016)

Aim To investigate pain, activities of daily living (ADL) function, sport function, quality of life and satisfaction at different time points after hip arthroscopy in patients with femoroacetabular impingement (FAI). Design Systematic review with meta-analysis. Weighted mean differences between preoperative and postoperative outcomes were calculated and used for meta-analysis. Data sources EMBASE, MEDLINE, SportsDiscus, CINAHL, Cochrane Library, and PEDro. Eligibility criteria for selecting studies Studies that evaluated hip pain, ADL function, sport function and quality of life before and after hip arthroscopy and postoperative satisfaction in patients with symptomatic FAI. Results Twenty-six studies (22 case series, 3 cohort studies, 1 randomised controlled trial (RCT)) were included in the systematic review and 19 in the meta-analysis. Clinically relevant pain and ADL function improvements were first reported between 3 and 6 months, and sport function improvements between 6 months and 1 year after surgery. It is not clear when quality of life improvements were first achieved. On average, residual mild pain and ADL and sport function scores lower than their healthy counterparts were reported by patients following surgery. Postoperative patient satisfaction ranged from 68% to 100%. Conclusions On average, patients reported earlier pain and ADL function improvements, and slower sport function improvements after hip arthroscopy for FAI. However, average scores from patients indicate residual mild hip pain and/or hip function lower than their healthy counterparts after surgery. Owing to the current low level of evidence, future RCTs and cohort studies should investigate the effectiveness of hip arthroscopy in patients with FAI. Trial registration number CRD42015019649.
Role of Stromal Microenvironment in Non-Pharmacological Resistance of CML to Imatinib through Lyn/CXCR4 Interactions.
Authors: Yoko Tabe, Linhua Jin, Yixin Zhou, Naoki Ichikawa, Kazuhisa Iwabuchi, Takashi Miida, Jorge Cortes, Michael Andreeff, Marina Konopleva
Journal: Blood (2009)
Autologous Stem Cell Transplant in Recurrent Diffuse Large B- Cell Lymphoma: Prior Rituximab Therapy Has No Impact On Early Lymphocyte Recovery and Transplant Outcome.
Authors: Daniel G Stover, Vishruth K Reddy, John P. Greer, Madan Jagasia, David Morgan, Brian Engelhardt, Adetola A. Kassim, Stacey Goodman, Carole Hunt, Friedrich Schuening, Bipin N. Savani, Nishitha Reddy
Journal: Blood (2009)
Intraductal necrosectomy for pancreatic walled-off necrosis using novel single-operator pancreatoscope
Authors: Takeshi Ogura, Wataru Takagi, Saori Onda, Tastsushi Sano, Kazuhide Higuchi
Journal: Endoscopy (2016)

A digital catheter-based single-operator cholangiopancreatoscope (SpyGlass DS Direct Visualization System; SPY DS, Boston Scientific) has recently become available. The scope of the SPY DS model shows marked improvements over the conventional SpyGlass system: (i) insertion into the biliary tract is easier because of the tapered tip; (ii) better visualization is obtained with the 120° digital field of view; and (iii) newly added injection and suction functions may be carried out through a two-port adaptor. This system thus allows diagnosis by direct visualization, and performance of various therapeutic interventions. Herein, we present technical tips for intraductal necrosectomy for infected pancreatic walled-off necrosis (WON) using a novel single-operator pancreatoscope.
Antimyeloma In Vitro Activity Of 15-Deoxy-D12,14-Prostaglandin J2 Is Associated With Endoplasmic Reticulum Stress In a Reactive Oxygen Species-Dependent Fashion
Authors: Ana Paula Demasi, Marcelo Henrique Napimoga, Elizabeth Ferreira Martinez, Adriana Silva Santos Duarte, Fernando V Pericole, Sara T O Saad, Ney Soares Araujo, Vera Cavalcanti Araujo
Journal: Blood (2013)
RUNX1 Mutations Can Be Found in 34% of De Novo AML with Normal Karyotype or Single Chromosomal Imbalances and Are Associated with Good Prognosis but Turn to Unfavourable Outcome If Further Cytogenetic or Molecular Mutations Are Acquired
Authors: Susanne Schnittger, Frank Dicker, Nicole Wendland, Tamara Weiss, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach
Journal: Blood (2008)
Chanarin–Dorfman syndrome with rare renal involvement
Authors: S.B. Verma, A. Mittal, U. Wollina, G.H. Eckstein, K. Gohel, K. Giehl
Journal: British Journal of Dermatology (2016)

A 17 year old male patient with no known history of a consanguineous marriage of the parents was referred to one of us (SV) by a nephrologist for erythroderma. He was earlier treated for nephritic syndrome with gradually worsening edema and proteinuria over a period of one week with a marginally raised creatinine. (2.4 mg/d). After four weeks of treatment with 0.5 mg/kg prednisolone in a tapering dose and diuretics the patient had a normal kidney function, normal electrolytes but a subnephrotic range proteinuria. According to the parents the boy was ‘covered in scales’ on the 3rd day of birth and the condition persists till date. He had a short stature (1.47 meters) with coarse facial features.

This article is protected by copyright. All rights reserved.
Pre-Treatment Serum Soluble Interleukin-2 Receptor Value Significantly Predicts Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma.
Authors: Shinsuke Noguchi, Masanobu Nakata, Kanako Shima, Yuki Katsura, Toshihiro Matsukawa, Minoru Kanaya, Satomi Matsuoka, Mizuha Kosugi, Shiro Fujii, Shuichi Ota, Kiyotoshi Imai, Teiichi Hirano, Naoki Kobayashi, Masahiro Ogasawara, Yoshio Kiyama, Masaharu Kasai
Journal: Blood (2009)
Imatinib Mesylate Discontinuation in Patients with Chronic Myelogenous Leukemia in Complete Molecular Remission: An Update Follow Up.
Authors: Francois-Xavier Mahon, Francoise Huguet, Gabriel Etienne, Delphine Réa, Jean-Michel Cayuela, Gerald Marit, Martine Gardembas, Josy Reiffers, Rousselot Philippe
Journal: Blood (2006)
FRI0353 A Longitudinal Analysis of Change in Lupus Disease Activity Pattern in Hopkins Lupus Cohort Using A Multistate Markov Model Approach: Table 1.
Authors: W. Fu, M. Petri
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic Lupus Erythematosus (SLE) is a multi-systemic inflammatory disease with extreme variability of its activity over time. We have described three main patterns: long quiescence (LQ), chronic activity (CA) and relapsing-remitting (RR). Patients may move through a series of these activity states over time. To capture these complex fluctuations, we used a Multistate Markov model to evaluate SLE disease activity patterns over time in a longitudinal lupus cohort. <h3>Objectives</h3> To describe burden of disease activity patterns over time among patients with SLE. To estimate the probability of transition between disease activity patterns and survival at 1, 2 and 5 years after SLE diagnosis. To identify predictors of change in disease activity patterns. <h3>Methods</h3> SLE patients were followed up quarterly in Hopkins Lupus Cohort for 1–28 years. Medication, disease activity (by Physician Global Assessment (PGA) and SLE Disease Activity Index (SLEDAI)), C3, C4, anti-dsDNA, antiphospholipid antibodies and urine protein/creatinine ratio were recorded at each visit. For each patient, visits were divided into 1-year blocks. Any 1-year block with only one visit or patients followed for only 1 year were excluded. SLE disease activity patterns were defined using PGA and SLEDAI. LQ: SLEDAI/PGA=0 for all visits within 1-year blocks; RR: periods of disease activity (SLEDAI/PGA&gt;0) interspersed with periods of disease inactivity (SLEDAI/PGA=0) within 1-year block; CA: SLEDAI/PGA&gt;0 for all visits within 1-year block. Multistate Markov models were used to provide estimates of relative transition rates and identify predictors of change in disease activity patterns. <h3>Results</h3> 1735 SLE patients were included in this analysis. 92.3% were females, mean ± SD age 32.8±13.1 years at diagnosis. 52.9% were Caucasian and 40.3% African American, the remainders were mostly Asian. 127 patients died during follow up. Likelihood of deterioration (LQ to RR; RR to CA; LQ to CA) was greater than improvement (RR to LQ; CA to RR; CA to LQ). At year 1, 63.6% remained in LQ, while at year 2 and year 5, 58.2% and 84.1% had deteriorated from LQ pattern to either RR or CA pattern. From the RR pattern, the estimated probability for deterioration (to CA pattern) was higher than improvement (to LQ pattern), regardless of years since SLE diagnosis. Multivariate analysis (see table 1) identified that race/ethnicity (African American), low C3, low C4, ESR &gt;20, taking prednisone, plaquenil or anti-hypertension drug were predictors for deterioration. Plaquenil improved survival. <h3>Conclusions</h3> 1 year after SLE diagnosis, more than half of patient with LQ deteriorated. Patients in RR were more likely to deteriorate than improve. Plaquenil showed great promise in improving survival. <h3>Disclosure of Interest</h3> None declared
THU0327 Comparison of Immunoenzymatic Assay and Crithidia Immunofluorescence Test for The Detection of anti-Double Strand Dna Antibodies in Patients with Systemic Lupus Erythematosus: Table 1.
Authors: G. Orsolini, M.R. Snyder, C.S. Crowson, J.L. Frinack, M.G. Kevin
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Anti double strand DNA (dsDNA) antibodies are one of the immunologic hallmarks used to identify patients with systemic lupus erythematosus (SLE). However, they can be seen in patients with other connective tissue diseases (CTDs) on occasion. These auto-antibodies can also be drug-induced by medications such as anti-TNF<i>α</i> agents. Different methods are available for their detection. In the past, radioimmunoassays (RIA) and immunofluorescence by Crithidia (CLIFT) were commonly used. More recently, immunoenzymatic assays (ELISA) have been widely utilized. ELISA assays are much faster, cheaper and easier to perform than other methods such as CLIFT and now are the most common method used by immunology laboratories. The Crithidia test is still used in clinical practice, often for the purpose of confirmation after ELISA or further testing if ELISA is negative, but its real usefulness needs to be more clearly defined. <h3>Objectives</h3> Investigate the relation between dsDNA Abs measured by CLIFT and ELISA. Define the clinical role for CLIFT testing. <h3>Methods</h3> 1000 consecutive adult patients tested for anti dsDNA by ELISA in Mayo Clinic Rochester immunology lab from September to December 2015 had their sera tested also by CLIFT. Laboratory, clinical data and history were reviewed. For ELISA we used Quanta Lite dsDNA ELISA kit by Inova Diagnostic, taking as stated by the manufacturer for negative value below 30 IU/ml, for borderline between 30 and 75 IU/ml and for positive above 75 IU/ml. For CLIFT we used Crithidia Luciliae Kit by Kallestad, considering positive the samples with immunofluorescence signal from the kinetoplast or from both the kinetoplast and the nucleus. <h3>Results</h3> CLIFT showed a very high specificity (99%) but a low sensitivity (14%) for patients with SLE. ELISA had specificity close to CLIFT (92–95%) but with a substantially better sensitivity (36–47%). ELISA performed better considering borderline as negative (positive predictive value [PPV] with borderline as negative 68% vs 63% as positive). <h3>Conclusions</h3> CLIFT is very specific but its low sensitivity limits its usefulness. New generation ELISA has good performance, with high specificity and good sensibility. A negative test by ELISA is most of the time negative also by Crithidia, and among the rare ELISA-/CLIFT+ few patients have SLE, so there9s no need to run Crithidia in ELISA negative patents. Among the ELISA positive, Crithidia could add value for some patients with SLE, but always keeping in mind the limit of sensitivity. <h3>Disclosure of Interest</h3> None declared
The Histone Deacetylase Inhibitor SAHA Induces Caspase-Dependent Apoptosis in Chronic Lymphocytic Leukemia Cells.
Authors: Laurence Lagneaux, Nathalie Meuleman, Alain Delforge, Marielle Dejeneffe, Martine Massy, Christine Mortier, Dominique Bron
Journal: Blood (2005)
A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.
Authors: Mark Levis, B. Douglas Smith, Miloslav Beran, Maria R. Baer, Harry P. Erba, Larry Cripe, Steven Coutre, Anjali Advani, Alexander Perl, Marcel Devetten, Robert Stuart, Martin S. Tallman, Peter Brown, Lothar Tremmel, Donald Small
Journal: Blood (2005)
Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months
Authors: Nicolas Williet, Gilles Boschetti, Marion Fovet, Thomas Di Bernado, Pierre Claudez, Emilie Del Tedesco, Camille Jarlot, Leslie Rinaldi, Anne Berger, Jean-Marc Phelip, Bernard Flourie, Stéphane Nancey, Stéphane Paul, Xavier Roblin
Journal: Clinical Gastroenterology and Hepatology (2016)
TC11, a Novel Phthalimide Derivative, Directly Binds to NPM1 and Induced Apoptosis of High-Risk Myeloma Cells Via Centrosomal Disruption
Authors: Saito Sosei, Kana Yoshikawa, Noriko Tabata, Hiroshi Yanagawa, Tsukasa Oikawa, Wenlin Du, Taketo Yamada, Maiko Matsushita, Junya Seki, Kaoru Tohyama, Yutaka Hattori
Journal: Blood (2012)
Syngeneic Blood and Marrow Transplantation: A Report of 94 Cases From Chinese Society of Blood and Marrow Transplantation (CSBMT).
Authors: Dao-Pei Lu, Tong Wu, Jih-Luh Tang, Raymond Liang, Albert Kwok Wai Lie, Hu Chen, Mao-Quan Qin, Ping Zou, Qi-Fa Liu, Fan-Yi Meng, Cheng-Lu Yuan, Wan-Ming Da, Jing Chen, Xing-Hua Chen, Xi Zhang, De-Pei Wu, Bo-Long Zhang, Jun Ma, Jian-Min Wang, Wei-Ping Zhang, Hai Bai, Deng-Ming Hu, Zi-Min Sun, Ming-Zhe Han, Si-Zhou Feng, Po-Min Chen, Hui-Ren Chen, Wen-Ming Chen, Zhi-Zhe Chen, Zhi-Sheng Jiang, Jiong Hu, Hui Liang, Ting Liu, Jing-Wen Wang, Yi-Cheng Zhang, Hui Sun, Ren-Wei Huang, Xu-Dong Li, Shu-Quan Ji, Hua Jiang
Journal: Blood (2009)
The Effect of Neurological Genomics and Personalized Mitochondrial Medicine
Authors: Rita Horvath, Patrick F. Chinnery
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Intensive vs Standard Blood Pressure Control for Older Adults
Authors: Charlotte Andersson, Ramachandran S. Vasan
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SAT0109 Subclinical Echocardiographic Characteristics in Patients with Rheumatoid Arthritis without Overt Cardiac Disease: Table 1
Authors: G. Orsolini, O. Viapiana, G. Cioffi, A. Dalbeni, A. Giollo, E. Fracassi, F. Ognibeni, D. Gatti, M. Rossini
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) have an increased risk for cardiovascular (CV) disease, despite preserved left ventricular (LV) ejection fraction (EF). Changes in LV geometry, LV systolic dysfunction (LVSD) and the development of excessive left ventricular mass (LVM) are closely and consistently associated with CV disease in several settings of patients such as those with arterial hypertension or type 2 diabetes mellitus, with preserved LVEF. <h3>Objectives</h3> The aim of this study was the evaluation of this subclinical parameters in patients with RA. <h3>Methods</h3> 198 outpatients with RA without overt cardiac disease were prospectively analyzed with echocardiography and compared with 198 matched controls. In all patient LV geometry (concentric remodeling or hypertrophy), LVEF, circumferential and longitudinal LVSD (respectively by stress-corrected midwall shortening [sc-MS] and Tissue Doppler mitral annular peak systolic velocity [S9]) and the presence of inappropriately high LVM (iLVM)were evaluated. <h3>Results</h3> The patients with RA present higher prevalence respect to controls ofconcentric remodeling or hypertrophy, circumferential or/and longitudinal LVSD and iLVM as reported on table. By multiple logistic regression analysis, rheumatoid arthritis emerged as independent predictor of all this echocardiography alterations. <h3>Conclusions</h3> The patients with RA without overt cardiac disease have the same echocardiographyc characteristics what are associated with CV disease in hypertension and in diabetes mellitus. These findings may be clinically useful for identifying a subgroup of patients with RA at very high risk for adverse CV events (mostly heart failure). Longitudinal studies are needed to assess the prognostic role of this conditions in these patients and to test conceivable and useful pharmacological and/or non-pharmacological treatments. <h3>Disclosure of Interest</h3> None declared
THE PREVALENCE OF INTESTINAL PROTOZOA AND RELATED ORGANISMS IN PORTO RICO
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB1073 Exploration of The Difficulties Encountered by General Practitioners with Methotrexate and Tnf-Inhibitor Treatment in Common Practice
Authors: E. Berthet, M. De Rosa, P. Vorilhon, M. Soubrier, S. Mathieu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatic diseases are frequently occurring pathologies (approximately 1% of the population exhibits rheumatoid arthritis), causing pain, articular destruction, and functional handicaps. Early diagnosis and regular disease monitoring are required in order to avoid such complications. The therapy9s objective is to attain remission, which entails optimal use of long-term treatments, such as methotrexate (MTX) or TNF-alpha inhibitors (anti-TNF alpha). These treatments are then increasingly prescribed. General practitioners (GPs) therefore must be able to manage such treatments, along with their potential side-effects. <h3>Objectives</h3> Our study9s aim was to explore the potential difficulties of GPs from the Auvergne region of France with regard to using anti-TNF alpha and MTX in their common practice. <h3>Methods</h3> A questionnaire collecting the GPs9 characteristics, difficulties in daily clinical practice, and expectations designed to ease the management of MTX and anti-TNF alpha treatments was mailed to 1,190 GPs in our region. <h3>Results</h3> The response rate was 24.9%, equating to 296 responses. The analysis covered 285 responses, since 11 doctors did not wish to participate. The majority of doctor respondents was men (57%) and was in group practice settings (55%). No respondents had practices situated at more than 100 km from a rheumatologist. Of the 230 GPs treating patients on MTX (81%: 230/285), 113 reported difficulties in managing therapy, such as infectious problems (30%) and the occurrence of side-effects (23%). Overall, 31% were troubled by potential drug interactions. GPs practicing for less than 10 years had more difficulties than the others (p=0.002). No significant differences were observed based on practice location, type of practice, or distance from the rheumatologist. In total, 22% of doctors surveyed (n=41) were prepared to initiate MTX therapy. Of the 189 respondents (66%) managing patients on TNF inhibitors, 127 encountered similar difficulties, yet with a higher frequency (infectious problems: 53%; side-effects: 29%, and drug interactions: 39%). No differences were observed based on GPs characteristics. Overall, 57.2% of the GPs (163/285) felt that TNF-inhibitor therapies displayed a favorable benefit/risk ratio. Amongst the respondents, 80% (228/285) desired further training. <h3>Conclusions</h3> In our study, more than half of the GPs managing patients on MTX- or TNF-inhibitor therapy reported difficulties with the treatment. <h3>Disclosure of Interest</h3> None declared